Overview
North America Biotech Investment Roadshow is organized by BCIC Venture and Q Bay Center for connecting between investors and biotech startups. 5 high-quality Startups (selected from 30+) and 50+ VC investors will attend the roadshow.
Date
NYTime 10/16 8:00-10:30pm
BeijingTime 10/17 8:00-10:30am
Roadshow Process
Each startup will have 25 minutes to pitch their ideas to our investors and corporate partners. Slides needed. Followed by a 5-minute Q&A. The investors may ask questions to the start-ups, and provide feedback following their pitch (should time allow).
Agenda
Date & Time: NYTime Oct 16, 2022
8:00pm-8:30pm EST: Osmol Therapeutics
8:30pm-9:00pm EST: Cytosolix
9:00pm-9:30pm EST: Zero-to-One
9:30pm-10:00pm EST: Eubulus
10:00pm-10:30pm EST: Geode Therapeutics
Zoom Link with Registration:
https://us06web.zoom.us/webinar/register/WN_uGO2kpMwQEGWd_SZdPmzsw
Organizers:
Boston Chinese Investment Club (BCIC)
Boston Chinese Investment Club (BCIC) is a non-profit organization founded in 2010 with more 6000 professionals in Finance, Venture Capital, and various technology industries. It serves as Boston centered platform for exchanging ideas, knowledge, and information between US and China. Main activities include roadshows and conferences. BCIC Ventures is committed to deal sourcing the high-quality startups to investors.( https://bcicglobal.org/)
Q Bay
Q Bay Center is committed to promoting the sustainable growth of life sciences sector. The ultimate goal is not only financial support on biotech startups, but also connecting the life sciences industry, investors and researchers to spark collaboration and innovation. As part of an initiative aimed at increasing the competitiveness of life sciences research and commercialization in the global marketplace, Q Bay is actively interested in life science companies that have potential to improve patients’ lives. (https://qbay.com/)
Startups
Osmol Therapeutics
Osmol Therapeutics develops treatment to prevent chemotherapy-induced peripheral neuropathy. The company was founded in 2016 and is headquartered in New Haven, Connecticut. Osmol is developing a treatment to prevent CIPN before it starts. Data from preclinical studies conducted by Osmol show that pretreatment with OSM-0205 prevents neuronal damage from taxanes in mice by preventing the off-target intracellular calcium surge caused by these chemotherapy agents. It is hypothesized that OSM-0205 in patients will protect neurons from damage leading to a reduction of CIPN. This prevention of CIPN will allow more optimal chemotherapy dosing.
Cytosolix
Cytosolix develops novel oral and IV derivatives that target tumor acidity to improve the efficacy of small molecule cancer therapeutics. Cytosolix’s Tumor Activated Permeability System, produces weakly-acidic derivatives of known oncology drugs, that enhance the uptake by cancer cells while restricting the uptake by healthy cells, enablingphysicians to get safer and more effective therapy for drugs with dose-limiting toxicities.
Zero-to-One
Zero-to-One (ZTO) is a life sciences commercialization company based in Cambridge, MA. ZTO partners with leading academic researchers to create therapeutics startups developing novel treatments for highly valuable patient addressable markets. ZTO’s model fills a critical early stage gap in the biotech innovation pipeline by identifying category-leading science and applying an experienced team of drug development and company-building experts to form and advance new venture-backable startups. Our interests are also in areas of prevention and aspects of care that can positively impact lives, improve health outcomes and reduce societal economic burden, and we work closely with thought leaders and experts to investigate synergies and overlaps between biotech and public health.
Eubulus
Eubulus Biotherapeutics Inc. was established in 2018, dedicated to the development of cell/tissue-targeted protein-degradation drugs (PROTACs, molecular glue). The core members of Eubulus Bio R&D team have more than 20 years of successful drug development experience in multinational pharmaceutical companies and cutting-edge biopharmaceutical companies, covering all key processes from innovative target selection, drug molecule structure optimization to drug launch. The pipelines of Eubulus Bio are committed to unmet medical needs, and the R&D emphasizes the construction of key technologies platform. In the hot areas of protein degradation drugs, Eubulus Bio established the TED platform that addresses the challenges faced by PROTAC drug development and focuses on solving the problem of poor draggability of molecules, and has made significant progress. The technologies are highly differentiated and have broad application prospects. In the new field of ferroptosis drug discovery, Eubulus Bio is in a global leader position for ferroptosis inducers discovery for oncology. The novel chemical series possess good drug likeness property.
Geode Therapeutics
PTEN is a major tumor suppressor and the key negative regulator of PI3K activity. Loss of PTEN function (PTEN-deficiency) is the most common mechanism leading to hyper-activation of PI3K signaling related to tumor initiation, progression, metastasis, and therapeutic resistance across nearly all types of cancer. PTEN-deficient cancer represents roughly ~120,000 new cases yearly in the United States, with many more patients worldwide. Early clinical trials with pan-PI3K inhibitors showed limited efficacy and significant toxicity in most patients with PTEN-deficient tumors. To date, there is no approved therapy specifically designed to treat PTEN-deficient cancer. Geode Therapeutics is built upon a deep understanding of the PI3K/PTEN pathway, and the diseases associated with its malfunction, as well as drug discovery. Through a series of seminal studies, Drs. Zhao and Roberts (Geode’s co-founders) have shown that tumors driven by PTENloss are uniquely dependent on the PI3Kβ isoform. Using our unique model systems and technology platform integrated with AI-assisted rational design, Geode is focusing on developing a robust pipeline of well-differentiated and novel therapeutic agents, including targeted drugs and immune modulatory agents to target PI3Kβ and beyond. Our lead series are rationally designed and optimized to be a potent and highly selective PI3Kβ inhibitors (Geode, PCT/US22/13725). We are quickly advancing our clinical candidate (GT220) to the clinical stage to transform the treatment landscape for patients afflicted with PTEN-deficient disease.
Boston Chinese Investment Club (BCIC) is a non-profit organization founded in 2010 with more 6000 professionals in Finance, Venture Capital, and various technology industries. It serves as a Boston centered platform for exchanging ideas, knowledge, and information in finance and related areas between US and China. Main activities include summits, conferences, and seminars. （https://bcicglobal.org/）
